According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

The authors are encouraged to carefully review all subtitles and figure legends to correct these errors and enhance readability. In the present study, the authors, using a mouse model of Fragile X ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, the most common genetically-caused autism ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

See part one of Imogen’s pregnancy diary which reveals why she was dumbstruck when she found out she was pregnant here.